Efficacy and Safety of Nefecon in Patients with IgA Nephropathy from Mainland China: 2-Year NefIgArd Trial Results
Kidney360 · 2024
DOI: 10.34067/kid.0000000583 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Kidney360, 2024. Verfasst von Hong Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Renal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China. Hauptthemen laut MEDLINE: Glomerulonephritis, IGA. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Calliditas Therapeutics, Everest Medicines.
Abstract (Originalsprache)
Key Points In the NefIgArd trial China cohort, 9 months of nefecon treatment led to clinically relevant preservation of kidney function over 2 years. Durable proteinuria reduction was also observed over 2 years with 9 months of nefecon treatment. These results were consistent with those of the global study population and support the disease-modifying effects of nefecon.
Background
IgA nephropathy (IgAN), an immune-mediated kidney disease, is particularly prevalent among individuals of East Asian ancestry. Nefecon is a novel, oral, targeted-release budesonide formulation designed to inhibit galactose-deficient IgA1 formation underlying IgAN pathophysiology. We present findings in patients with IgAN from mainland China participating in the 2-year, multicenter, randomized, double-blind, phase 3 NefIgArd trial of nefecon.
Methods
Patients (aged 18 years and older) with primary IgAN (eGFR 35–90 ml/min per 1.73 m 2 , persistent proteinuria [urine protein–creatinine ratio ≥0.8 g/g or proteinuria ≥1 g/24 hours] despite optimized renin-angiotensin system blockade) received nefecon or placebo over 9 months, followed by a 15-month follow-up phase on supportive care alone. The primary efficacy end point was time-weighted average of eGFR over 2 years.
Results
Sixty-two patients from mainland China were included in this prespecified analysis. The primary efficacy end point was 9.6 ml/min per 1.73 m 2 (95% confidence interval, 2.0 to 19.8) in favor of nefecon versus placebo. This was consistent with (and numerically greater than) that of the global study population. Time to confirmed 30% eGFR reduction or kidney failure from baseline was substantially delayed with nefecon (patients with an event: 9%) versus placebo (30%; hazard ratio, 0.21; 95% confidence interval, 0.04 to 0.73). No deaths were reported in the China cohort. In the nefecon group, treatment-emergent serious adverse events were reported by one patient during treatment and two patients during follow-up (versus no patients and seven patients, respectively, in the placebo group). No severe infections requiring hospitalization were reported.
Conclusions
Nefecon treatment for 9 months showed greater preservation of eGFR over 2 years compared with placebo. The efficacy outcomes were consistent with global study results, with a numerically greater treatment benefit observed in patients from China. Nefecon was well tolerated, with no unexpected safety signals. Clinical Trial registry name and registration number: Efficacy and Safety of Nefecon in Patients With Primary IgAN, NCT03643965.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Renal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China.
- Division of Nephrology, Department of Medicine, Stanford University, Stanford, California.
- Everest Medicines Ltd., Shanghai, China.
- Stone Biostatistics Ltd., Crewe, United Kingdom.
- JDK Pharmaconsulting, Espergarde, Denmark.
- The Mayer IgA Nephropathy Laboratories, Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom.
ORCID-Profile: Richard Lafayette, Jonathan Barratt
Förderung
- Calliditas Therapeutics, Everest Medicines
Zitieren
APA
Zhang, H., Lafayette, R., Wang, B., Ying, L., Zhu, Z., Stone, A., Kristensen, J., & Barratt, J. (2024). Efficacy and Safety of Nefecon in Patients with IgA Nephropathy from Mainland China: 2-Year NefIgArd Trial Results. Kidney360. https://doi.org/10.34067/kid.0000000583
Vancouver
Zhang H, Lafayette R, Wang B, Ying L, Zhu Z, Stone A, et al. Efficacy and Safety of Nefecon in Patients with IgA Nephropathy from Mainland China: 2-Year NefIgArd Trial Results. Kidney360. 2024. doi:10.34067/kid.0000000583
BibTeX
@article{Zhang2024,
author = {Zhang, Hong and Lafayette, Richard and Wang, Bei and Ying, Lisa and Zhu, Zhengying and Stone, Andrew and Kristensen, Jens and Barratt, Jonathan},
title = {Efficacy and Safety of Nefecon in Patients with IgA Nephropathy from Mainland China: 2-Year NefIgArd Trial Results},
journal = {Kidney360},
year = {2024},
doi = {10.34067/kid.0000000583}
}
EUVIMED